5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.

      1 , , ,
      Biomaterials science
      Royal Society of Chemistry (RSC)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this study, cisplatin (cis-diaminedichloroplatinum, CDDP) nanocarriers with phosphorylcholine surface tailoring were developed to enhance the anti-tumor potential of CDDP for the treatment of osteosarcoma. Poly(2-methacryloyloxyethyl phosphorylcholine)-b-poly(methacrylic acid) (PMPC-b-PMAA) was synthesized for the preparation of CDDP/PMPC-b-PMAA micelles. The synthesis, self-assembly, and in vitro drug release were well characterized. In vitro cytotoxicity showed that CDDP/PMPC-b-PMAA micelles can strongly inhibit the proliferation of Saos-2 cells. In vivo experiments indicated that CDDP/PMPC-b-PMAA micelles showed prolonged circulation time, reduced renal accumulation, and enhanced tumor accumulation compared to free CDDP. Overall, the CDDP/PMPC-b-PMAA micelles exhibited optimal anti-tumor activity with minimal side effects in the treatment of osteosarcoma.

          Related collections

          Author and article information

          Journal
          Biomater Sci
          Biomaterials science
          Royal Society of Chemistry (RSC)
          2047-4849
          2047-4830
          Aug 19 2016
          : 4
          : 8
          Affiliations
          [1 ] Department of Orthopedics, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, P. R. China. zepzj@163.com.
          Article
          10.1039/c6bm00331a
          27315174
          4fa6a0ac-a0d8-4e4c-a3b6-8bfdbf5c3f7d
          History

          Comments

          Comment on this article